INTRODUCTION: Dissolution is the required characterization test to evaluate new materials for transdermal drug delivery [1]. However the conventional dissolution tests, recommended by United State Pharmacopeia (USP), cannot provide results with good correlation with in vivo drug release, especially for patches that mainly depends on skin resistance to drug diffusion [2]. Other dissolution metho...

OBJECTIVE Evaluation of the use of testosterone therapy for hypoactive sexual desire disorder (HSDD) after oophorectomy has mostly involved women treated with oral estrogen preparations. We investigated the efficacy and safety of a testosterone patch in surgically menopausal women receiving concurrent transdermal estrogen. DESIGN Women with HSDD after oophorectomy, for whom this was a concern...

UNLABELLED SUMMARY  AIM To evaluate the use of transdermal buprenorphine patches (Transtec®) in routine clinical practice. PATIENTS & METHODS A prospective, noninterventional, postmarketing study performed in the Czech Republic by 71 investigators in various clinical practice settings. Patients with chronic moderate-to-severe cancer pain, or chronic severe noncancer pain insufficiently cont...

Transdermal drug delivery is the application of drug on the skin surface so that it can permeate through the skin and reaches the systemic circulation at sufficient concentration to ensure therapeutic efficacy. Transdermal drug delivery system (TDDS) has several advantages over conventional system; TDDS offers sustained drug release, avoidance of first pass effect, patient compliance, ease of a...

OBJECTIVES To evaluate the effects of transdermal estrogen therapy on bone mineral density (BMD) in postmenopausal Korean women. METHODS A total of 149 healthy postmenopausal women were retrospectively evaluated: 100 were on hormone therapy (HT) and 49 were the control group. For the HT group, 54 applied estrogen transdermally using either a patch (n = 21) or gel (n = 33), and 46 took estroge...

Here we report a novel approach for preparation of a 6-day transdermal drug delivery system (TDDS) as treatment for mild to moderate Alzheimer's disease. The spray drying method was used to prepare microparticles containing the anti-Alzheimer drug, Rivastigmine, in combination with the natural polymer, chitosan, for transdermal drug delivery applications. The content of the drug was determined ...

BACKGROUND AND OBJECTIVES Rotigotine is a dopamine receptor agonist with activity across the D1 through to D5 receptors as well as select serotonergic and adrenergic sites; continuous transdermal delivery of rotigotine with replacement of the patch once daily maintains stable plasma concentrations over 24 h. Rotigotine is indicated for the treatment of early and advanced-stage Parkinson's disea...

Skin permeability and local blood perfusion are important factors for transdermal drug delivery. Application of heat is expected to enhance microcirculation and local perfusion and/or blood vessel permeability, thus facilitating drug transfer to the systemic circulation. In addition, heating prior to or during topical application of a drug may facilitate skin penetration, increase kinetic energ...

The objective of this study was to develop a transdermal therapeutic system for meloxicam (MX) using various polymers like hydroxy propyl methyl cellulose (HPMC), ethyl cellulose (EC) and polyvinyl pyrrolidone (PVP) and plasticisers by solvent casting technique. The prepared patches were evaluated for physicochemical properties, in vitro release, in vitro skin permeation and in vivo release. Th...

The use of the transdermal contraceptive patch is associated with greater bioavailability of ethinyl estradiol (EE) compared with contraceptive vaginal ring or oral contraceptives (OC). We compared the influences of three contraceptive methods (OC, vaginal ring, and transdermal patch) on serum levels of coenzyme Q(10), alpha-tocopherol, gamma-tocopherol and total antioxidant capacity in premeno...